7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Xu S et al. | Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. | 2012 | Rheumatol. Int. | pmid:22057136 |
| Skoumal M et al. | The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. | 2008 | Rheumatol. Int. | pmid:18075741 |
| Kanbe K et al. | Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. | 2012 | Rheumatol. Int. | pmid:21789615 |
| Oelzner P et al. | The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. | 2012 | Rheumatol. Int. | pmid:20821212 |
| Rooney T et al. | Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. | 2010 | Rheumatol. Int. | pmid:19847430 |
| Hein GE et al. | sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. | 2008 | Rheumatol. Int. | pmid:18172654 |
| Stupphann D et al. | Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. | 2008 | Rheumatol. Int. | pmid:18369625 |
| Yun HJ et al. | Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. | 2009 | Rheumatol. Int. | pmid:19116717 |
| Agarwal S et al. | Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. | 2009 | Rheumatol. Int. | pmid:19052752 |
| Zhou J et al. | Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. | 2013 | Rheumatol. Int. | pmid:22948539 |
| Keller KK et al. | SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes. | 2013 | Rheumatol. Int. | pmid:22948540 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Yao Y et al. | Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. | 2013 | Rheumatol. Int. | pmid:23334376 |
| Pamuk BO et al. | Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. | 2013 | Rheumatol. Int. | pmid:23358733 |
| Chen J et al. | OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell. | 2012 | Rheumatol. Int. | pmid:22210270 |
| Kwon SR et al. | Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. | 2012 | Rheumatol. Int. | pmid:21833531 |
| Upton AR et al. | The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. | 2012 | Rheumatol. Int. | pmid:21259010 |
| Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
| Ciacli C et al. | [Bone turnover markers evaluation in psoriatic arthritis]. | 2008 Jul-Sep | Rev Med Chir Soc Med Nat Iasi | pmid:20201244 |
| Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
| Sasso GR et al. | Elevated serum osteoprotegerin levels in women: friend or foe? | 2015 Nov-Dec | Rev Assoc Med Bras (1992) | pmid:26841162 |
| Riancho JA and Delgado-Calle J | [Osteoblast-osteoclast interaction mechanisms]. | 2011 | Reumatol Clin | pmid:21924211 |
| Bogliolo L et al. | Biomarkers and prognostic stratification in psoriatic arthritis. | 2012 | Reumatismo | pmid:22690385 |
| Bai P et al. | Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. | 2011 | Respir. Res. | pmid:22176920 |
| Pobeha P et al. | Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. | 2014 | Respir Med | pmid:24424018 |
| Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
| Heymann MF et al. | OPG, RANK and RANK ligand expression in thyroid lesions. | 2008 | Regul. Pept. | pmid:18367263 |
| Kadoglou NP et al. | Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. | 2012 | Regul. Pept. | pmid:22982141 |
| Minenna G et al. | [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. | 2005 | Recenti Prog Med | pmid:16229324 |
| Kahl KG et al. | Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. | 2006 Sep-Oct | Psychosom Med | pmid:17012519 |
| Janda K et al. | [The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients]. | 2012 | Prz. Lek. | pmid:23750431 |
| Czyzewska-Buczyńska A et al. | [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients]. | 2013 | Prz. Lek. | pmid:24003660 |
| Ziółkowska H and Roszkowska-Blaim M | [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. | 2006 | Prz. Lek. | pmid:16898492 |
| Komosińska-Vassev K et al. | [Osteoporosis--pathophysiology and laboratory diagnostic methods]. | 2010 | Prz. Lek. | pmid:21387765 |
| Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
| Helo S et al. | Role of denosumab in prostate cancer. | 2012 | Prostate Cancer Prostatic Dis. | pmid:22370723 |
| Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
| Vandyke K et al. | Androgen decreases osteoprotegerin expression in prostate cancer cells. | 2007 | Prostate Cancer Prostatic Dis. | pmid:17189957 |
| Armstrong AP et al. | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. | 2008 | Prostate | pmid:18008334 |
| Corey E et al. | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. | 2002 | Prostate | pmid:11992617 |
| Hesry V et al. | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. | 2006 | Prostate | pmid:16541419 |
| Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
| Zheng Y et al. | Vitamin D deficiency promotes prostate cancer growth in bone. | 2011 | Prostate | pmid:21541977 |
| Yonou H et al. | Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. | 2007 | Prostate | pmid:17394194 |
| Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Poulsen RC et al. | Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. | 2008 | Prostaglandins Other Lipid Mediat. | pmid:18077200 |
| Li X et al. | Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. | 2002 | Prostaglandins Other Lipid Mediat. | pmid:12013525 |
| Kuroyanagi G et al. | (-)-Epigallocatechin gallate synergistically potentiates prostaglandin E2-stimulated osteoprotegerin synthesis in osteoblasts. | 2017 | Prostaglandins Other Lipid Mediat. | pmid:28163121 |
| Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |